COR
Cencora, Inc.
COR has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over COR overall, supported by stronger fundamentals and stronger modeled upside.
COR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Stable |
COR's profitability is currently healthy, and its revenue, cash flow and balance sheet are stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
COR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 18x | $237 | -32% |
| Forward | 18x | $349 | — |
| Fair | 24x | $320 | -8.3% |
| Current | 26x | $349 | — |
| Expensive | 33x | $450 | +29% |
Historical ranges are pointers, not guarantees.
COR's PE is in its expensive range at 26x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over COR in the historical PE scenario, which offers more potential upside but is not a forecast.
COR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Stable | |
| Limited | |
| High |
Analysts expect COR's earnings to grow, with its revenue and profitability holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over COR on the outlook, with more favorable revenue and profitability expectations.
COR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $19.77 | +47% |
| Q2 2026 | $13.47 | +38% |
| Q1 2026 | $13.05 | +51% |
| Q4 2025 | $8.33 | +18% |
COR's earnings per share have climbed steadily: $13.47 over the past year, up 38% from the year before, and higher year over year every quarter since late 2025.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over COR in the latest year-over-year earnings comparison.
COR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $88.4B | +5.5% |
| Q2 2026 | $84.8B | +5.1% |
| Q1 2026 | $78.4B | +3.8% |
| Q4 2025 | $85.9B | +5.5% |
COR's revenue has grown year over year every quarter since late 2025: $88.4B last quarter, up 5.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 1.3% | +0.2 points |
| Q1 2026 | 1.5% | +0.1 points |
| Q4 2025 | 0.9% | 0 points |
| Q3 2025 | 0% | N/A |
| Q2 2025 | 1.1% | N/A |
| Q1 2025 | 1.4% | N/A |
| Q4 2024 | 0.9% | N/A |
COR's operating margin was 1.3% last quarter, about level with the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over COR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over COR on profitability, with a higher operating margin.
COR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $2.4B | +$2.5B |
| Q1 2026 | $1.2B | -64% |
| Q4 2025 | -$2.4B | +$400.1M |
COR and OSCR do not have enough comparable growth data to identify a winner.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
COR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -1.4M shares |
| 1 year | -0.7% | -1.3M shares |
COR has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $1B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $71,000 |
| Q2 2025 | — |
| Q1 2025 | $50M |
| Q4 2024 | $385.4M |
COR spent $1B buying back its own shares over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
COR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 2.2x | Moderate |
| Q1 2026 | 2.7x | Moderate |
| Q4 2025 | 1.7x | Healthy |
| Q3 2025 | 0.9x | Very low |
| Q2 2025 | 1.6x | Healthy |
| Q1 2025 | 1.6x | Healthy |
| Q4 2024 | 1.6x | Healthy |
COR's net debt is about 2.2 years of its operating earnings (EBITDA), up from 1.6 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over COR on leverage, with a lower net debt burden relative to earnings.
COR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 63.7 | Neutral |
| Stochastic | 68.6 | Neutral |
COR's weekly RSI is 64 (neutral) and its Stochastic is 69 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
COR PE vs Healthcare Sector
| Metric | COR | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 26x | 0.3% above |
| PE % | 68 | 29 | 39 pts above |
COR is trading at 26x earnings, in line with the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over COR on valuation relative to its sector.
COR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $328.2 | 6.5% above |
| 20 week MA | $319.5 | 9.3% above |
| 50 week MA | $321.3 | 8.7% above |
| 100 week MA | $304.2 | 15% above |
| 200 week MA | $255.0 | 37% above |
COR is in an uptrend: it's above all five of its weekly moving averages, and 37% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
COR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $84.9 | $97.0 | +14% |
| 2021 | $97.0 | $129.5 | +34% |
| 2022 | $129.5 | $170.0 | +31% |
| 2023 | $170.0 | $205.4 | +21% |
| 2024 | $205.4 | $226.9 | +10% |
| 2025 | $226.9 | $341.1 | +50% |
| 2026 YTD | $341.1 | $349.4 | +2.4% |
COR has finished every year since 2020 higher, and it's up 2.4% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over COR on returns for 2026, with the stronger performance.